Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00573651 · ClinicalTrials.gov registry record · NA

Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis

A NA study of Arthritis, sponsored by University Hospitals Cleveland Medical Center.

Completed
Registry status
NA
Development phase
43
Enrollment target
4
Study locations

NCT00573651 is a NA study of Arthritis that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 43 participants, below the 4,509-participant average among 48 other Arthritis trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00573651, a NA study of Arthritis, has completed, sponsored by University Hospitals Cleveland Medical Center.

COMPLETED
Registry status
NA
Development phase
43 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this research study is to see if patients with juvenile idiopathic arthritis or seronegative arthritis (and related conditions) mount protective immune responses to the human papillomavirus (HPV) vaccine called Gardasil. The researchers also want to monitor for any increase in disease activity following receipt of the vaccine.

Conditions Studied

Interventions

  • OTHER Blood Draws for Serum Titers

Study Locations (4)

Ohio

  • University Hospitals Medical Center - Cleveland
  • MetroHealth Medical Center - Cleveland
  • Cleveland Clinic - Cleveland

Illinois

  • University of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2007-11
Est. Completion 2014-10-20
Phase NA

What the Registry Record Tells You About NCT00573651

The ClinicalTrials.gov registry entry for NCT00573651 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,509-participant average among 48 other Arthritis trials with a reported enrollment target (99% lower). The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Blood Draws for Serum Titers is the first listed.

NCT00573651 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Illinois.

Frequently Asked Questions

What is clinical trial NCT00573651 about?

NCT00573651 is a clinical study titled "Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis". The purpose of this research study is to see if patients with juvenile idiopathic arthritis or seronegative arthritis (and related conditions) mount protective immune responses to the human papillomavirus (HPV) vaccine called Gardasil. The researchers also want to monitor for any increase in disease...

What is the current status of trial NCT00573651?

This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2007-11. Estimated completion is 2014-10-20.

What conditions does trial NCT00573651 study?

This clinical trial studies the following conditions: Arthritis.

What interventions are being tested in trial NCT00573651?

The interventions under investigation include: Blood Draws for Serum Titers (OTHER).

Who is sponsoring clinical trial NCT00573651?

This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00573651 being conducted?

This trial has 4 study locations across Illinois, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.